Report Code: A13398 | Nov 2023 | Pages: NA | ||
Tables: NA | Charts: NA |
|
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Herpangina Treatment Market
Request Now !Herpangina is a viral infection that causes sores in the mouth. It is a very contagious disease that normally affects small children from 3 to 10 years of age, though adults and teenagers can also get it. Herpangina is caused by a virus and the most common viruses responsible are Echovirus, Coxsackie A16, Enterovirus 71, Coxsackie B. It is spread through saliva, respiratory droplets, stool or directly touching fluid from a sore. Symptoms can differ depending on which virus causes the infection. Herpangina is treated by controlling symptoms. The illness will be varied depending on the severity of the infection, the child’s age, and general health. As herpangina is a viral infection, antibiotics will not benefit.
COVID-19 Impact analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the herpangina treatment market.
Top Impacting Factors
Key Benefits of the Report
Questions answered in the herpangina treatment Report
Herpangina Treatment Market Report Highlights
Aspects | Details |
---|---|
By Virus |
|
By Symptoms |
|
By Treatment |
|
By End User |
|
By Region |
|
Key Market Players | ViiV Healthcare group of companies, Gilead Sciences, Inc., Mitsubishi Tanabe Pharma Corporation, F. Hoffmann-La Roche Ltd, Vertex Pharmaceuticals Incorporated, AbbVie Inc., Sanofi S.A, GlaxoSmithKline Plc, Merck & Co., Inc., Pfizer Inc., Novartis AG, Johnson and Johnson Services, Inc. |
Start reading.
This Report and over 67,068+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers